Major global firms ranging from banks to chipmakers are taking a largely cautious stance on their China business amid a frail recovery at the world's second-largest economy from a pandemic slowdown.
Following are comments from some of the top firms on their China business during the latest reporting season:doubled in China in the first half.third-quarter comparable sales surging 46 per cent.growth driver for the human papillomavirus vaccine.International boosted its earnings.its response to price cuts in China hurt its results there.